Background
End-stage renal disease (ESRD) is a life-threatening disease that requires appropriate and sequential selection and ordering of available therapies. Dialysis and kidney transplantation are the currently used replacement therapies, and kidney transplantation is the best option to prolong the patient's life. Most patients require dialysis as they wait for transplantation; however, the impact of pretransplant dialysis on the posttransplant graft and patient survival has produced conflicting results. A number of studies have demonstrated that the modality of dialysis does not affect the outcomes [1] [2] [3] [4] . However, other studies have indicated an increased survival for patients and grafts treated by peritoneal dialysis (PD) or, on the contrary, increased graft survival by hemodialysis (HD) [5] [6] [7] [8] , despite the fact that the 2 largest studies using national datasets in the 21st century have yielded conflicting results [8, 9] . From previous studies, it has been found that short-term posttransplant complications such as acute rejection (AR) and delayed graft function (DGF) have also made differences [1, 5, 6, [9] [10] [11] [12] . In such situations, a meta-analysis can be helpful to assess whether a true difference exists; the purpose of this systematic review and meta-analysis was to explore which pretransplant dialysis modality yielded better results.
Method

Search Strategy
Two independent investigators (M.T., T.L.) conducted a systematic review of published peer-reviewed research articles by searching the PubMed, EMBASE and the Cochrane central register of controlled trials databases for all years. The search was conducted using the following terms: 'peritoneal dialysis', 'hemodialysis', 'dialysis modality', 'kidney transplant * ' and 'transplant outcome'. We reviewed reference lists for additional citations.
Inclusion and Exclusion Criteria
Studies were eligible for inclusion in the review if they met the following criteria: (1) randomized controlled trial (RCT) or cohort study; (2) assessed at least one of the following outcomes: patient survival, graft survival, AR, or DGF; (3) patients underwent kidney transplant after 1990; and (4) were English articles only. Studies were excluded if they met the following criteria: (1) were review papers, conference abstracts, thesis, news, and non-peer-reviewed articles; (2) the patients were children; and (3) the sample size was less than 100 cases.
Quality Assessment
Quality assessment was based on the Newcastle-Ottawa Scale [13] with the following items: (1) the exposed cohort was truly representative; (2) the cohort was drawn from the same community; (3) ascertainment of exposure; (4) outcome of interest not present at start; (5a) cohorts comparable in age; (5b) cohorts comparable on other factor(s); (6) quality of outcome assessment; (7) followup long enough for outcomes to occur; and (8) complete accounting for cohorts. All studies were rated on each indicator (1 star for 'yes' and 0 stars for 'no') for a total score between 0 and 9; the quality assessment is shown in table 1 .
Data Extraction
Two independent reviewers abstracted data from the included studies using modified Cochrane Back Review Group criteria [14] . We extracted the following information: first author and published year, region, study design, sample size, the follow-up time and posttransplant outcomes.
Statistical Analysis
All statistical calculations were performed using Stata version 12.0 (StataCorp LP, College Station, Tex., USA). We estimated the heterogeneity between studies with Cochran's Q (reported as χ 2 [15] . I 2 does not inherently depend on the number of studies included; the suggested options included using 25, 50 and 75% to indicate low-, moderate-, and high-level heterogeneity. In meta-analyses, a random effects model using the DerSimonian and Laird method is assumed if high levels of heterogeneity are observed [15] . Hazard ratios (HRs) were used to estimate the 5-year patient and graft survival analyses. HRs and their variance for each individual study were extracted or calculated based on the published studies according to the methods described by Parmar et al. [16] . Kaplan-Meier curves were read by Engauge Digitizer version 4.1 (http://digitizer.sourceforge.net/). ORs were used to measure the risk of posttransplant complications. Publication bias was not performed because of the small sample size. Significance was set at a p value of <0.05. Figure 1 summarizes the process of identifying eligible studies. Our initial search criteria identified 1,058 articles from 3 electronic databases and hand review, and 921 studies remained after removing duplicated articles. Titles were screened among the remaining 921 studies, and 733 were excluded because they were not relevant. The 188 remaining studies were screened based on the abstracts; 137 studies were excluded because 12 were reviews, letters or comments, and 125 were excluded because they were not relevant to the topic. A total of 51 studies were eligible for full-text screening, and 24 studies were further excluded because they were not RCTs or cohort studies. Three articles were excluded because of their small sample size, and the other 12 studies that included patients who underwent transplantation before 1990 were excluded. The remaining 12 studies (6 studies reported survival analysis, 9 studies reported DFG and 6 studies reported AR) were eligible for the final meta-analysis. Table 1 depicts the baseline characteristics of the 12 included retrospective cohort studies; they were single-center studies, 2 were multicenter studies and 2 were databasebased studies. Six studies of 187,886 ESRD patients were included in the analysis of patient survival [6] [7] [8] [9] [10] 17] 
Results
Flow of Included Studies
Baseline Characteristics of the Included Studies
Short-Term Post-Transplant Complications
DGF and AR were the main short-term posttransplant complications. Figure 2 shows the meta-analysis of DGF and AR for pretransplant PD compared with pretransplant HD, which indicated that PD patients had a significantly lower risk of DGF than the HD patients with an OR 0.67 (95% CI 0.62-0.72); however, moderate heterogeneity was observed (I 2 = 54.5%). Additionally, PD patients had a lower risk of AR than HD patients, yielding an OR 0.96 (95% CI 0.75-1.16), and no heterogeneity was observed (I 2 = 0%); however, the difference was not significant. Figure 3 shows the pooled HR of posttransplant 5-year patient survival rates for pretransplant PD compared with pretransplant HD. We found that PD patients had a higher 5-year patient survival rate than HD patients, yielding an HR 0.86 (95% CI 0.79-0.95, p < 0.05) but with high heterogeneity (I 2 = 79.3%). Figure 4 shows the pooled HR of posttransplant 5-year graft survival rates for pretransplant PD compared with pretransplant HD, which indicated no significant differences between the 2 modalities, with an HR 0.92 (95% CI 0.84-1.01, p = 0.08). Additionally, Goldfarb-Ru- myantzev's study with 92,844 patients designed a 10-year follow-up evaluation that suggested that PD patients had a protective effect for graft survival (HR 0.97, p < 0.05) and better recipient survival (HR 0.96, p < 0.05) compared to HD patients [8] .
Long-Term Outcomes of Transplantation
Discussion
The first meta-analysis on this topic was conducted by Winchester et al. [20] in 1993 to evaluate the effects of pretransplant dialysis on the posttransplant outcomes. However, there have not been updated analyses for 20 years; hence, the attempt to compose a new study to explore the question. Similar to all observational meta-analyses, selection bias cannot be definitively excluded in these retrospective cohort studies, and the diversity of baseline characteristics among the studies led to heterogeneity.
Confounding factors in each study such as age, body mass index, time of dialysis, frequency of dialysis, year of transplantation, geographical region and use of immunosuppressive drugs could not be well controlled or matched.
Studies have shown that chronic renal insufficiency leads to a micro-inflammation condition through accumulation of inflammasomes and metabolites and that artificial membranes used in HD could increase free radical production by activating complement factors and phagocyte leucocytes; this oxidative stress contributes to DGF [21, 22] . On the other hand, PD patients had better cellmediated immune states and less oxidative stress than HD patients [23, 24] . Additionally, PD modality had a protective effect on renal functional recovery after transplantation due to optimized fluid status [11] . All of the factors mentioned above may have been associated with the higher incidence of DFG in HD patients vs. PD patients. One other explanation for this result was the possibility that residual native kidney function was better preserved in PD patients than in HD patients [25, 26] .
HD as a pretransplant modality may have a higher incidence of AR because patients receiving artificial membranes in HD may induce stronger immune responses than patients receiving PD. Furthermore, HD patients with a higher incidence of DGF may contribute to the increased incidence of AR [27, 28] . On the other hand, ESRD patients undergoing chronic HD exhibit impaired cellular immune response with a marked reduction in the naïve and central memory subsets of CD4+ and CD8+ T cells, and the total circulating T cells are significantly lower in HD than in PD patients [29, 30] . Furthermore, PD patients are typically accompanied by greater biochemical and hematological stability due to improved nutritional balance and social independence enjoyment, consequently preventing metabolic and nutritional harm to the immune system, with a better immunologic state contributing to a higher incidence of AR in PD patients than in HD patients [20, [30] [31] [32] [33] . Hence, the debate has not yet reached any consensus. However, our meta-analysis found that there were no significant differences between the 2 pretransplant modalities in the incidences of AR, with an OR 0.96 (95% CI 0.75-1.16), which may have benefited from the use of immunosuppressive agents. Snyder et al. [9] in a study of 22,776 patients suggested that PD patients had a higher risk of graft failure than HD patients during the first 3 months after transplantation with an adjusted OR 1.23 (95% CI 1.09-1.39). These results could be explained by a higher incidence of infections and early graft thrombosis in PD patients [33] [34] [35] [36] . Typically, PD patients have a better immunologic state, which could have an adverse effect on the outcome of graft survival [30] . However, in our meta-analysis of 5-year observations, we found no significant differences in the graft survival rate between the 2 dialysis modalities with an HR 0.92 (95% CI 0.84-1.01, p = 0.08). In our meta-analysis, we found that PD patients had a better 5-year patient survival than HD patients, with an HR 0.86 (95% CI 0.79-0.95, p < 0.05); this was associated with a better quality of life, better nutritional status and fewer blood transfusions in PD patients. Additionally, the use of novel immunosuppressive drugs contributed to prolonging a patient's life [37] [38] [39] . One limitation of the study was that we did not evaluate long-term, posttransplant complications such as posttransplant diabetes mellitus, malignancy and cardiovascular accidents, which are still under debate.
In conclusion, we found that pretransplant dialysis does influence the short-and long-term complications after kidney transplantation and that PD as a pretransplant dialysis modality seems to be a better choice than HD. However, a 5-year observation was not sufficient to evaluate graft and patient survival; 10-year follow-up studies are therefore needed, especially for prospective studies.
